http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2315040-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0c9faa155d463b43beea07486b35df63 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2004-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2009-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb5b226188b23ae4abac06a3c5d8fd32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9bd77325de426a2183a425957d53ebc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c2aae5fae41edf18b9baa7db0d04db9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4830100d1393066bb85a5b7cf2ed3df9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_693ed0a28b0c2e7180b090e8232e1a30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e9efcc95a560e1e4edbc5e2c604c80a |
| publicationDate | 2009-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2315040-B2 |
| titleOfInvention | PROCEDURE TO DETERMINE THE EFFECTIVENESS OF THE TREATMENT AND THE PROGRESSION DEGREE OF CHRONIC MYELOID LEUKEMIA BY USING SPI-1 / PI.1. |
| abstract | Procedure to determine the efficacy of the treatment and the degree of progression of chronic myeloid leukemia through the use of SPI-1 / PU.1 consisting of the determination of mRNA or protein of the SPI-1 / PU.1 gene, in samples of blood or bone marrow cells of CML patients and their comparison with samples from healthy subjects or the same patient after antileukemic treatment. SPI-1 / PU.1 mRNA or protein levels high or comparable to those of healthy subjects are indicators of treatment response. The presence of SPI-1 / PU.1 is an indicator of response to treatment and recovery of normal hematopoiesis. On the contrary, a reduced expression is an indicator of leukemia persistence and poor prognosis. |
| priorityDate | 2004-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 83.